SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover rumorsdescribed as interest from an unnamed West Coast technology companydominate discussion, with traders speculating about Meta while others question whether any bid exists. The chatter sits alongside anticipation for PayPals Q3 earnings and debate over whether its business fundamentals can support a recovery without a deal.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

ABCL635s Phase 2 results for menopausal hot flashes and its presentation of further clinical data are driving attention, with new analyst coverage adding to interest. Bulls view the results as validation of AbCelleras pipeline, while more cautious traders argue that the gains may already reflect expectations and that durability and further clinical progress remain to be shown.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines weaker outlook, with elevated jet-fuel costs expected to squeeze earnings despite record revenue, is driving the discussion and weighing on shares. Traders are divided between those betting the bad news is priced in and a rebound is possible, and those concerned that persistently high fuel costs and AALs debt will keep pressure on the business.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Choppy Russell 2000 trading is fueling debate over whether small caps are beginning to rotate higher as technology weakens: some traders point to IWMs resilience and a potential rebound, while others cite weak breadth, resistance and bearish options positioning. Oil and uncertainty around U.S.Iran tensions, alongside rate and recession concerns, are adding to the cautious outlook.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook and suspension of its dividend to prioritize debt reduction have fueled a steep selloff. Traders are debating whether recession-level appliance demand and financial strain leave room for a turnaround, while many blame management and warn of further downside.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

BCHs sharp swings and breakout speculation dominate the discussion, with traders attributing a rally to CME futures access and a Grayscale filing. Optimism about further gains is met with skepticism over pullbacks, BCHs utility, and its performance relative to Bitcoin.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartis/Aviditys failed Phase 3 DM1 trial has fueled sympathy selling in Sarepta, while traders debate whether the result undermines SRP-1003 or mainly weakens a competitor. The community is focused on Sareptas upcoming DM1 and FSHD readouts to test whether its distinct delivery approach can translate target knockdown into functional benefit.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is drawing attention amid a steep decline and repeated concern over the $1 level, with discussion also focused on claims that a Hyperbridge exploit involved minting and selling a large amount of wrapped DOT. Some traders dispute that this means native DOT was compromised, while others remain focused on the tokens weak price action and lack of demand.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The TRUMP meme coins prolonged decline is drawing attention, with many traders criticizing it as a Trump-family cash grab and lamenting losses among holders. A smaller bullish camp is still calling for a rebound or short squeeze, leaving discussion sharply divided but predominantly bearish.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas pivotal HLP003 Phase 3 APPROACH readout for major depressive disorder, which the company has guided to Q4 2026. Traders are weighing optimism about the treatments potential as an add-on to existing antidepressants against the binary risk of the results, with concerns about possible dilution and volatile trading also recurring.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -30.77% and -10.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences Q1 Earnings Call Highlights...

BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline

BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline...

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Bionano Genomics (BNGO) delivered earnings and revenue surprises of +6.17% and +2.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know

BioHarvest Sciences Inc. (BHST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This account has been verified as an official BHST representative.

Verified Account

BioHarvest Sciences

BioHarvest Sciences, Inc. develops bio-cell growth platform technology. The firm engages in botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions. It offers nutraceutical health and wellness products, which includes dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients. The company was founded on April 19, 2013 and is headquartered in Vancouver, Canada.

BioHarvest Sciences Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.72
Prev Close	$1.68
Open	$1.83
Dividend Yield	0.00%
50-Day Moving Average	$1.74
Beta	-32.48
Avg. Volume	35,862.86
PE Ratio	-3.28

52-Week High	$12.20
52-Week Low	$1.37
Market Capitalization	$38.99M
EPS (Annual)	-$0.6048
Price to Book	1.97
Revenue Per Employee	$387,730.34

Feed

News

Sentiment

Earnings

Fundamentals

Info

BHST Fundamentals